Promise of mGluR2/3 activators in psychiatry
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The group II metabotropic glutamate receptors (mGluRs), mGluR2 and mGluR3, have emerged as exciting and well-validated targets for novel therapeutic agents used for treating psychiatric disorders. A large number of preclinical and clinical studies provide strong evidence that mGluR2/3 agonists may provide a novel approach to treatment of anxiety disorders and schizophrenia. Group II mGluR agonists, such as LY354740 and related compounds, have robust activity in a range of animal models that predict anxiolytic (Swanson et al, 2005) and antipsychotic (Schoepp and Marek, 2002) activities. Furthermore, clinical studies reveal that group II mGluR agonists have robust efficacy in human models of panic attack and fear-potentiated startle (Swanson et al, 2005) and improve ratings for positive and negative symptoms in patients suffering from schizophrenia (Patil et al, 2007). In these trials, there were no major liabilities associated with current medications, including sedation, amnesic symptoms, withdrawal upon discontinuation of the drug, prolactin elevation, extrapyramidal symptoms, or weight gain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Metabotropic glutamate receptors as novel targets for anxiety and stress disorders
Swanson, C. J., Bures, M., Johnson, M. P., Linden, A.-M., Monn, J. A., & Schoepp, D. D. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1630 · Cited by 607
Cited by
Duman, R. S. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.3/rsduman · Cited by 210
Glutamatergic targets for new alcohol medications
Holmes, A., Spanagel, R., & Krystal, J. H. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3226-2 · Cited by 197
“Of these, there has been growing interest in developing pharmacotherapies for alcoholism around the glutamate system (Spanagel and Vengeliene 2013), as there has been for anxiety disorders (Conn and Jones 2009), depression (Skolnick et al.”
BackgroundAhnaou, A., Ver Donck, L., & Drinkenburg, W. H. I. M. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.003 · Cited by 31
Metadata
- Authors
- Conn, P. J., & Jones, C. K.
- Venue
- Neuropsychopharmacology
- Published
- 2008-12-12
- Volume
- 34
- Issue
- 1
- Pages
- 248-249
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1979981960
- Cited by
- 39
- References
- 2
- FWCI
- 0.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Promise of mGluR2/3 activators in psychiatry. https://app.cochat.ai/papers/10.1038/npp.2008.156
- The paper
- Conn, P. J., & Jones, C. K. (2009). Promise of mGluR2/3 activators in psychiatry. Neuropsychopharmacology. https://doi.org/10.1038/npp.2008.156
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.